Cogent Biosciences is a biopharmaceutical company focused on developing curative cell therapies for solid tumors. Co.'s proprietary technology includes its Bolt-On Chimeric Receptor platform, designed to discover bolt-on transgenes to improve the functionality of engineered T cells and overcome resistance of the solid tumor microenvironment to T cell attack. Co. has also developed product candidates using its proprietary technology, Antibody-Coupled T cell Receptor, an autologous engineered T-cell investigational therapy that is designed to combine the cell-killing ability of T cells and the tumor-targeting ability of co-administered antibodies to exert antitumor immune responses. The COGT stock yearly return is shown above.
The yearly return on the COGT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the COGT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|